Lexeo Therapeutics (NASDAQ:LXEO) Price Target Cut to $18.00 by Analysts at Leerink Partners

Lexeo Therapeutics (NASDAQ:LXEO) had its price objective cut by Leerink Partners from $19.00 to $18.00 in a research note published on Monday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $23.60.

Lexeo Therapeutics Stock Up 50.9 %

Shares of NASDAQ LXEO opened at $4.09 on Monday. The firm’s 50 day moving average price is $4.15 and its 200 day moving average price is $6.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The firm has a market cap of $135.24 million, a P/E ratio of -1.29 and a beta of 3.85. Lexeo Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.09. As a group, sell-side analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allostery Investments LP purchased a new position in shares of Lexeo Therapeutics in the 4th quarter worth about $33,000. BNP Paribas Financial Markets increased its position in Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Lexeo Therapeutics in the fourth quarter valued at approximately $46,000. JPMorgan Chase & Co. raised its holdings in Lexeo Therapeutics by 135.6% in the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock valued at $93,000 after buying an additional 5,915 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new position in Lexeo Therapeutics during the fourth quarter valued at approximately $69,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.